Matthew Taylor
Stock Analyst at Jefferies
(3.32)
# 1,068
Out of 4,667 analysts
177
Total ratings
60%
Success rate
10.86%
Average return
Main Sectors:
Stocks Rated by Matthew Taylor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Hold | $120 → $125 | $115.93 | +7.82% | 12 | Oct 17, 2024 | |
| EW Edwards Lifesciences | Downgrades: Hold | $85 → $70 | $69.54 | +0.66% | 19 | Sep 18, 2024 | |
| PODD Insulet | Maintains: Neutral | $211 → $223 | $266.58 | -16.35% | 14 | Aug 9, 2024 | |
| INMD InMode | Downgrades: Hold | $21 → $19 | $18.24 | +4.17% | 6 | Jul 23, 2024 | |
| MDT Medtronic | Maintains: Sell | $75 → $76 | $84.11 | -9.64% | 17 | May 24, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $5 | $0.46 | +992.18% | 1 | Feb 9, 2024 | |
| MASI Masimo | Downgrades: Hold | $107 → $121 | $164.95 | -26.64% | 9 | Jan 30, 2024 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $14 | $5.28 | +165.15% | 1 | Jan 19, 2024 | |
| GEHC GE HealthCare Technologies | Initiates: Hold | $80 | $84.90 | -5.77% | 1 | Nov 30, 2023 | |
| TNDM Tandem Diabetes Care | Maintains: Buy | $47 → $45 | $30.15 | +49.25% | 2 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $0.5 | $0.32 | +57.58% | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $58 → $53 | $22.93 | +131.14% | 2 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $22 → $24 | $15.42 | +55.64% | 2 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $345 | $385.68 | -10.55% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $115 → $130 | $109.27 | +18.97% | 8 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $239.20 | -3.85% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $12.15 | +64.61% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $85 | $70.69 | +20.24% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $83.59 | -10.28% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $245 | $241.55 | +1.43% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $88 | $49.00 | +79.59% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $62 | $32.63 | +90.01% | 8 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $187.43 | +12.04% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $9.93 | +20.85% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $75.24 | +66.14% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $90.17 | -44.55% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $541.82 | -61.24% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $31 | $4.23 | +632.86% | 5 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $96 | $50.05 | +91.81% | 3 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $7 | $3.32 | +110.84% | 1 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $266 | $222.39 | +19.61% | 4 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $16 | $6.74 | +137.39% | 2 | Jul 19, 2017 |
Abbott Laboratories
Oct 17, 2024
Maintains: Hold
Price Target: $120 → $125
Current: $115.93
Upside: +7.82%
Edwards Lifesciences
Sep 18, 2024
Downgrades: Hold
Price Target: $85 → $70
Current: $69.54
Upside: +0.66%
Insulet
Aug 9, 2024
Maintains: Neutral
Price Target: $211 → $223
Current: $266.58
Upside: -16.35%
InMode
Jul 23, 2024
Downgrades: Hold
Price Target: $21 → $19
Current: $18.24
Upside: +4.17%
Medtronic
May 24, 2024
Maintains: Sell
Price Target: $75 → $76
Current: $84.11
Upside: -9.64%
Allurion Technologies
Feb 9, 2024
Initiates: Buy
Price Target: $5
Current: $0.46
Upside: +992.18%
Masimo
Jan 30, 2024
Downgrades: Hold
Price Target: $107 → $121
Current: $164.95
Upside: -26.64%
Orchestra BioMed Holdings
Jan 19, 2024
Initiates: Buy
Price Target: $14
Current: $5.28
Upside: +165.15%
GE HealthCare Technologies
Nov 30, 2023
Initiates: Hold
Price Target: $80
Current: $84.90
Upside: -5.77%
Tandem Diabetes Care
Oct 2, 2023
Maintains: Buy
Price Target: $47 → $45
Current: $30.15
Upside: +49.25%
Jul 19, 2023
Initiates: Underperform
Price Target: $0.5
Current: $0.32
Upside: +57.58%
Jul 12, 2023
Upgrades: Buy
Price Target: $58 → $53
Current: $22.93
Upside: +131.14%
May 24, 2023
Maintains: Hold
Price Target: $22 → $24
Current: $15.42
Upside: +55.64%
May 2, 2023
Maintains: Buy
Price Target: $320 → $345
Current: $385.68
Upside: -10.55%
Mar 31, 2023
Upgrades: Hold
Price Target: $115 → $130
Current: $109.27
Upside: +18.97%
Oct 12, 2022
Initiates: Buy
Price Target: $230
Current: $239.20
Upside: -3.85%
Oct 12, 2022
Initiates: Buy
Price Target: $20
Current: $12.15
Upside: +64.61%
Oct 12, 2022
Initiates: Hold
Price Target: $85
Current: $70.69
Upside: +20.24%
Oct 12, 2022
Initiates: Buy
Price Target: $75
Current: $83.59
Upside: -10.28%
Oct 12, 2022
Initiates: Hold
Price Target: $245
Current: $241.55
Upside: +1.43%
Oct 12, 2022
Initiates: Buy
Price Target: $88
Current: $49.00
Upside: +79.59%
Oct 12, 2022
Initiates: Hold
Price Target: $62
Current: $32.63
Upside: +90.01%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $187.43
Upside: +12.04%
Oct 12, 2022
Initiates: Buy
Price Target: $12
Current: $9.93
Upside: +20.85%
Oct 12, 2022
Initiates: Buy
Price Target: $125
Current: $75.24
Upside: +66.14%
Oct 12, 2022
Initiates: Buy
Price Target: $50
Current: $90.17
Upside: -44.55%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $541.82
Upside: -61.24%
Oct 12, 2022
Initiates: Underperform
Price Target: $31
Current: $4.23
Upside: +632.86%
Feb 24, 2022
Upgrades: Buy
Price Target: $96
Current: $50.05
Upside: +91.81%
Dec 17, 2021
Initiates: Neutral
Price Target: $7
Current: $3.32
Upside: +110.84%
May 13, 2019
Upgrades: Overweight
Price Target: $266
Current: $222.39
Upside: +19.61%
Jul 19, 2017
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $6.74
Upside: +137.39%